Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Reports Q2 revenue $55.26B, consensus $54.97B. “We delivered strong second quarter financial results while taking significant strategic and ...

Management raised fiscal 2025 EPS guidance to $7.85-$8, a $0.10 increase at the midpoint, reflecting strong Pharma performance and contributions from recent acquisitions. The company expects Q3 to be ...

Consensus $7.86. The company said, “The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to ...

Dublin City Schools is withdrawing from an agreement to buy Cardinal Health’s headquarters for $37 million to serve as a high ...

Dublin City Schools is officially withdrawing from an agreement with Cardinal Health to purchase a vacant office building.

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against ...

Canadians Cardinal Michael Czerny and sculptor Timothy P. Schmalz on Thursday in Rome spoke about evangelization through art as part of festivities linked to the Jan. 24–26 Jubilee of the World ...